Orphanet: Búsqueda simple

Búsqueda de un ensayo clínico

Otra(s) opcion(es) de búsqueda

147 Resultado(s)

Ensayo(s) clínico(s) nacional(es)

Molecular and Cellular Print Medical Device Validation in Adult Glioma Tumors (Phase I) - FR Centre Hospitalier Universitaire Grenoble Alpes

INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies Deutsches Krebsforschungszentrum Klinische Kooperationseinheit Pädiatrische Onkologie

SIOP-LGG-2004: Radiation therapy or combination Chemotherapy in treating Patients with clinically or radiologically progressive Low-Grade Gliomas Universitätsklinikum Augsburg Schwäbisches Kinderkrebszentrum

INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies Universitätsklinikum Regensburg Abteilung für Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation

INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies Universitätsklinikum Essen Klinik für Kinderheilkunde III - Abteilung für pädiatrische Hämatologie und Onkologie

LAHENE Study: Perioperative Levetiracetam for seizure prophylaxis in brain tumor patients. Prospective evaluation of side effects and efficacy (phase 2) Universitätsklinikum St. Pölten Karl Landsteiner Institut für klinische Neurologie und Neuropsychologie

A Phase II, Open-label, Study in Subjects With BRAF V600E-Mutated Rare Cancers With Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib - AT Allgemeines Krankenhaus der Stadt Wien Klinische Abteilung für Onkologie

VINILO: Phase I-II Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults With Refractory or Recurrent Low-Grade Glioma - AT Allgemeines Krankenhaus der Stadt Wien Klinische Abteilung für Neonatologie, Pädiatrische Intensivmedizin und Neuropädiatrie

INFORM2 NivEnt: Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies - AT St. Anna Kinderspital Zentrum für Kinder- und Jugendheilkunde

Estudio de fase II, abierto, en sujetos con cánceres raros de diversas histologías con la mutación BRAF V600E para investigar la eficacia clínica y la seguridad del tratamiento combinado con dabrafenib y trametinib Hospital Universitari Vall d'Hebron Servicio de Oncología Médica

VINILO: Estudio fase I-II de vinblastina en combinación con nilotinib en niños, adolescentes, y adultos jóvenes con glioma de bajo grado refractario o recurrente Hospital Sant Joan de Déu Barcelona Servicio de Oncología y Hematología

Estudio de fase II, abierto, en sujetos con cánceres raros de diversas histologías con la mutación BRAF V600E para investigar la eficacia clínica y la seguridad del tratamiento combinado con dabrafenib y trametinib Hospital Universitario 12 de Octubre Servicio de Oncología Médica

Estudio de fase II, abierto, en sujetos con cánceres raros de diversas histologías con la mutación BRAF V600E para investigar la eficacia clínica y la seguridad del tratamiento combinado con dabrafenib y trametinib Clínica Universidad de Navarra Servicio de Oncología Médica

A Phase II Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas - US University of California San Diego University of California, San Diego

Cilengitide (EMD121974) in combination with irradiation in children and young adults with newly diagnosed diffuse intrinsic pontine glioma : Phase I study CLCC Oscar Lambret Unité d'oncologie pédiatrique

OVIMA : Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma CLCC Oscar Lambret Unité d'oncologie pédiatrique

A Study Evaluating Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia. A Phase III Double-blind Randomized Placebo-controlled Trial APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière Unité Fonctionnelle Epilepsie

BIOMEDE: Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication (Phase II) - FR CLCC Institut Gustave Roussy Département de Cancérologie de l'enfant et de l'adolescent

VINILO: Phase I-II Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults With Refractory or Recurrent Low-Grade Glioma - FR CLCC Institut Gustave Roussy Département de Cancérologie de l'enfant et de l'adolescent

Phase II, open label, monocentric, uncontrolled, non randomized clinical trial on Sodium Fluorescein for Surgery of High Grade Gliomas Fondazione IRCCS Istituto Neurologico "Carlo Besta" UOC Neurochirurgia 2 - Neurochirurgia Vascolare

Cooperative Multicenter Study for Children and Adolescents With Low Grade Glioma - PL Instytut "Pomnik-Centrum Zdrowia Dziecka" Klinika Onkologii IP-CZD

Cooperative Multicenter Study for Children and Adolescents With Low Grade Glioma - PT Centro Hospitalar de S. João, EPE Unidade de Hematologia e Oncologia Pediátrica

PARC: Phase I/II Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100) in Relapsed/Refractory Cancers of Children and Young Adults -GB University of Birmingham University of Birmingham HQ

CNS 2004 03: Cooperative Multicentre Study For Children And Adolescents With Low Grade Glioma (Phase III) (SIOP-LGG 2004) - UK St James's University Hospital Regional Paediatric Oncology Unit

CATNON (EORTC 26053-22054) - Phase III trial on concurrent and adjuvant Temozolomide chemotherapy in non-1p/19q deleted Anaplastic Glioma - DE Neurologische Universitätsklinik Heidelberg Abteilung für Neuroonkologie

EORTC 26052-22053 (RTOG 0525) : Phase III trial comparing conventional adjuvant Temozolomide with dose-intensive Temozolomide in patients with newly diagnosed Glioblastoma Neurologische Universitätsklinik Heidelberg Abteilung für Neuroonkologie

EORTC 26081-22086 (CODEL): Phase III intergroup study of Radiotherapy versus Temozolomide alone versus Radiotherapy with concomitant and adjuvant Temozolomide for patients with 1p/19q codeleted Anaplastic Glioma - DE Neurologische Universitätsklinik Heidelberg Abteilung für Neuroonkologie

TAVAREC (EORTC 26091) - Randomized trial assessing the significance of Bevacizumab in recurrent Grade II and Grade III Glioma (Phase II) - DE Neurologische Universitätsklinik Heidelberg Abteilung für Neuroonkologie

EORTC 26062-22061: A randomized phase III study of Temozolomide and short-course radiation versus short-course radiation alone in the treatment of newly diagnosed glioblastoma multiforme in elderly patients - DE Neurologische Universitätsklinik Heidelberg Abteilung für Neuroonkologie

EORTC 26101: Randomized phase II trial exploring the sequence of Bevacizumab and Lomustine in patients with first recurrence of a Glioblastoma Neurologische Universitätsklinik Heidelberg Abteilung für Neuroonkologie

A Phase II, multicenter, randomized, double-blind study of LY2157299 monohydrate monotherapy or LY2157299 monohydrate Plus Lomustine therapy compared to Lomustine monotherapy in patients with recurrent Glioblastoma - DE Neurologische Universitätsklinik Heidelberg Abteilung für Neuroonkologie

ABT-414 alone or ABT-414 plus Temozolomide versus Lomustine or Temozolomide for recurrent Glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group - DE Neurologische Universitätsklinik Heidelberg Abteilung für Neuroonkologie

NOA-20/Improvement of functional outcome for patients with newly diagnosed grade II or III glioma with co-deletion of 1p/19q - IMPROVE CODEL Neurologische Universitätsklinik Heidelberg Abteilung für Neuroonkologie

An open-label, Phase I/II multicenter clinical trial of VXM01 in combination with avelumab in patients with progressive glioblastoma following standard treatment with or without second surgery -DE- Neurologische Universitätsklinik Heidelberg Abteilung für Neuroonkologie

GERAS: Effect of Timing of Tumor-Treating Fields Plus Short-Course Radiation in Elderly Patients With Glioblastoma Neurologische Universitätsklinik Heidelberg Klinik für Radioonkologie und Strahlentherapie

Phase 3b Study for Management of Ocular Side Effects in Subjects With EGFR-amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414) -DE- Universitätsklinikum Heidelberg

Impact of iMRI on the Extent of Resection in Patients With Newly Diagnosed Glioblastomas - A Prospective Multicenter Parallel Group Clinical Trial - DE CCC Tübingen-Stuttgart Comprehensive Cancer Center Tübingen-Stuttgart

Phase 3b Study for Management of Ocular Side Effects in Subjects With EGFR-amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414) -DE- Universitätsklinikum Tübingen

GlioCave/NOA17: Adjuvant Stereotactic Fractionated Radiotherapy to the Resection Cavity in Recurrent Glioblastoma (Phase 2) - DE Klinikum rechts der Isar der Technischen Universität München Klinik und Poliklinik für RadioOnkologie und Strahlentherapie

Evaluation of the Feasibility of PD L 506 for Stereotactic Interstitial Photodynamic Therapy (iPDT) in Adult Patients With Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma LMU Klinikum der Universität München - Campus Großhadern Neurochirurgische Klinik und Poliklinik

Phase 3b Study for Management of Ocular Side Effects in Subjects With EGFR-amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414) -DE- Universität Regensburg

The C-GBM Study: Prospective controlled phase II trial of Cabazitaxel in patients with Temozolomide refractory Glioblastoma Multiforme - DE Charité - Universitätsmedizin Berlin (CVK) Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie

Phase 3b Study for Management of Ocular Side Effects in Subjects With EGFR-amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414) -DE- Hubertus Wald Tumorzentrum/ Universitäres Cancer Center (UCCH) Comprehensive Cancer Center (CCC) Hamburg

A prospective, multicenter phase III trial of NovoTTF-100A together with Temozolomide compared to Temozolomide alone in patients with newly diagnosed Glioblastoma Multiforme (GBM) UKE - Universitätsklinikum Hamburg-Eppendorf Klinik und Poliklinik für Neurochirurgie

HIT-HGG-CilMetro: Cilengitide and Metronomic Temozolomide for relapsed or refractory high grade Gliomas or Diffuse Intrinsic Pontine Gliomas in children and adolescents - Prospective non- randomised phase II study Universitätsmedizin Göttingen Klinik für Kinder- und Jugendmedizin

Autologous Dendritic Cells and Metronomic Cyclophosphamide for Relapsed High-Grade Gliomas in Children and Adolescents Universitätsmedizin Göttingen Klinik für Kinder- und Jugendmedizin

GLORIA: Single-arm, Dose-Escalation, Phase 1/2 Study of Olaptesed Pegol (NOX-A12) in Combination with Irradiation in Inoperable or Partially Resected First-line Glioblastoma Patients with Unmethylated MGMT Promoter Universitätsklinikum Bonn (AöR) Klinik und Poliklinik für Neurologie

Phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy in newly diagnosed glioblastoma -DE- Universitätsklinikum Düsseldorf Klinik für Neurochirurgie

GLORIA: Single-arm, Dose-Escalation, Phase 1/2 Study of Olaptesed Pegol (NOX-A12) in Combination with Irradiation in Inoperable or Partially Resected First-line Glioblastoma Patients with Unmethylated MGMT Promoter Universitätsklinikum Essen Klinik für Neurologie

Phase 3b Study for Management of Ocular Side Effects in Subjects With EGFR-amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414) -DE- Universitätsklinikum Leipzig AöR UCCL - Universitäres Krebszentrum Leipzig

MIRAGE: A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma - AT Institution: Information not provided - AT

IDH mutated 1p/19q intact lower grade glioma following resection: Wait Or Treat? IWOT - A phase III study - AT Institution: Information not provided - AT

Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma - AT Allgemeines Krankenhaus der Stadt Wien Klinische Abteilung für Onkologie

STEAM: Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma: A Phase Ib Study - AT Allgemeines Krankenhaus der Stadt Wien Klinische Abteilung für Onkologie

Pharmacokinetics of temozolomide in cerebrospinal fluid in children with malignant brain tumors (phase 1) Allgemeines Krankenhaus der Stadt Wien Klinische Abteilung für Neonatologie, Pädiatrische Intensivmedizin und Neuropädiatrie

EORTC 26081-22086/CODEL: Phase III intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with concomitant and adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma - BE Ziekenhuis Netwerk Antwerpen (ZNA) - Campus Middelheim Oncologie

ADDIT-GLIO: Adjuvant Dendritic-Cell Immunotherapy Plus Temozolomide Following Surgery and Chemoradiation in Patients With Newly Diagnosed Glioblastoma University Hospital of Antwerp - UZA Antwerp University Hospital

TAVAREC: Randomized trial assessing the significance of Bevacizumab in recurrent grade II and Grade III gliomas. The TAVAREC trial (Phase II) - BE Institution: Information not provided - BE

Phase IIb Trial Evaluations Of The Effectiveness Of Treatment Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 (Pembrolizumab) - BE Cliniques universitaires Saint-Luc - UCLouvain Cliniques Universitaires Saint-Luc

A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma Universitair Ziekenhuis Brussel NMRC Site UZBrussel

The CATNON Intergroup trial: Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma - BE Universitair Ziekenhuis Brussel Neurology

Phase II Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma Universitair Ziekenhuis Brussel Universitair Ziekenhuis Brussel (UZ Brussel)

CheckMate 548: Estudio fase 3, aleatorizado, simple ciego, de temozolomida más radioterapia combinados con nivolumab o placebo en sujetos adultos recién diagnosticados de glioblastoma con MGMT (06-metilguanina ADN metiltransferasa tumoral) metilado Hospital Germans Trias I Pujol

CheckMate 548: Estudio fase 3, aleatorizado, simple ciego, de temozolomida más radioterapia combinados con nivolumab o placebo en sujetos adultos recién diagnosticados de glioblastoma con MGMT (06-metilguanina ADN metiltransferasa tumoral) metilado Hospital Clínic de Barcelona

Estudio clínico de fase 2 de pomalidomida (CC-4047) en monoterapia para niños y adultos jóvenes con tumores cerebrales primarios recurrentes o progresivos Hospital Universitari Vall d'Hebron

CheckMate 548: Estudio fase 3, aleatorizado, simple ciego, de temozolomida más radioterapia combinados con nivolumab o placebo en sujetos adultos recién diagnosticados de glioblastoma con MGMT (06-metilguanina ADN metiltransferasa tumoral) metilado Hospital Universitari Vall d'Hebron

CheckMate 548: Estudio fase 3, aleatorizado, simple ciego, de temozolomida más radioterapia combinados con nivolumab o placebo en sujetos adultos recién diagnosticados de glioblastoma con MGMT (06-metilguanina ADN metiltransferasa tumoral) metilado Hospital General Universitario de Valencia

Estudio clínico de fase 2 de pomalidomida (CC-4047) en monoterapia para niños y adultos jóvenes con tumores cerebrales primarios recurrentes o progresivos Hospital Universitario y Politécnico La Fe

Ensayo de fase IIb de evaluación de la eficacia del tratamiento del glioblastoma / gliosarcoma mediante la supresión de la vía PI3K/Akt en comparación con MK-3475 (pembrolizumab) Institution: Information not provided - ES

Estudio clínico de fase 2 de pomalidomida (CC-4047) en monoterapia para niños y adultos jóvenes con tumores cerebrales primarios recurrentes o progresivos Hospital Infantil Universitario Niño Jesús

CheckMate 548: Estudio fase 3, aleatorizado, simple ciego, de temozolomida más radioterapia combinados con nivolumab o placebo en sujetos adultos recién diagnosticados de glioblastoma con MGMT (06-metilguanina ADN metiltransferasa tumoral) metilado Hospital Universitario 12 de Octubre

GEINOGLAS: Ensayo clínico fase Ib/II sobre la combinación de glasdegib (inhibidor de la vía SHH) y temozolamida en pacientes con diagnóstico de novo de glioblastoma Hospital Universitario Ramón y Cajal Servicio de Oncología Médica

A Phase I Study of Cytosine Deaminase-Expressing Neural Stem Cells in Combination With Oral 5-Fluorocytosine and Leucovorin for the Treatment of Recurrent High-Grade Gliomas - US City of Hope City of Hope National Medical Center

A Phase 2, Investigator Initiated Study to Determine the Safety and Efficacy of TH-302 in Combination With Bevacizumab for Glioblastoma Following Bevacizumab Failure - US University of Texas Health Science Center

Randomized, Prospective, Multicenter Blinding Singles With Arm A and Arm B Innovative Strategy Strategy Conventional (Phase III) - FR CHU de Lyon HCL - GH Est-Hôpital Neurologique P. Wertheimer Service de neurochirurgie tumorale - chirurgie des malformations vasculaires du systéme nerveux

GLYRad : Phase I/II Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma CLCC Jean Perrin

Molecular and Cellular Print Medical Device Validation in Adult Glioma Tumors (Phase I) - FR
Centre Hospitalier Universitaire Grenoble Alpes

INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Deutsches Krebsforschungszentrum

Klinische Kooperationseinheit Pädiatrische Onkologie

SIOP-LGG-2004: Radiation therapy or combination Chemotherapy in treating Patients with clinically or radiologically progressive Low-Grade Gliomas
Universitätsklinikum Augsburg

Schwäbisches Kinderkrebszentrum

INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Universitätsklinikum Regensburg

Abteilung für Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation

INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Universitätsklinikum Essen

Klinik für Kinderheilkunde III - Abteilung für pädiatrische Hämatologie und Onkologie

LAHENE Study: Perioperative Levetiracetam for seizure prophylaxis in brain tumor patients. Prospective evaluation of side effects and efficacy (phase 2)
Universitätsklinikum St. Pölten

Karl Landsteiner Institut für klinische Neurologie und Neuropsychologie

A Phase II, Open-label, Study in Subjects With BRAF V600E-Mutated Rare Cancers With Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib - AT
Allgemeines Krankenhaus der Stadt Wien

Klinische Abteilung für Onkologie

VINILO: Phase I-II Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults With Refractory or Recurrent Low-Grade Glioma - AT
Allgemeines Krankenhaus der Stadt Wien

Klinische Abteilung für Neonatologie, Pädiatrische Intensivmedizin und Neuropädiatrie

INFORM2 NivEnt: Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies - AT
St. Anna Kinderspital

Zentrum für Kinder- und Jugendheilkunde

Estudio de fase II, abierto, en sujetos con cánceres raros de diversas histologías con la mutación BRAF V600E para investigar la eficacia clínica y la seguridad del tratamiento combinado con dabrafenib y trametinib
Hospital Universitari Vall d'Hebron

Servicio de Oncología Médica

VINILO: Estudio fase I-II de vinblastina en combinación con nilotinib en niños, adolescentes, y adultos jóvenes con glioma de bajo grado refractario o recurrente
Hospital Sant Joan de Déu Barcelona

Servicio de Oncología y Hematología

Estudio de fase II, abierto, en sujetos con cánceres raros de diversas histologías con la mutación BRAF V600E para investigar la eficacia clínica y la seguridad del tratamiento combinado con dabrafenib y trametinib
Hospital Universitario 12 de Octubre

Servicio de Oncología Médica

Estudio de fase II, abierto, en sujetos con cánceres raros de diversas histologías con la mutación BRAF V600E para investigar la eficacia clínica y la seguridad del tratamiento combinado con dabrafenib y trametinib
Clínica Universidad de Navarra

Servicio de Oncología Médica

A Phase II Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas - US
University of California San Diego

University of California, San Diego

Cilengitide (EMD121974) in combination with irradiation in children and young adults with newly diagnosed diffuse intrinsic pontine glioma : Phase I study
CLCC Oscar Lambret

Unité d'oncologie pédiatrique

OVIMA : Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma
CLCC Oscar Lambret

Unité d'oncologie pédiatrique

A Study Evaluating Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia. A Phase III Double-blind Randomized Placebo-controlled Trial
APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière

Unité Fonctionnelle Epilepsie

BIOMEDE: Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication (Phase II) - FR
CLCC Institut Gustave Roussy

Département de Cancérologie de l'enfant et de l'adolescent

VINILO: Phase I-II Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults With Refractory or Recurrent Low-Grade Glioma - FR
CLCC Institut Gustave Roussy

Département de Cancérologie de l'enfant et de l'adolescent

Phase II, open label, monocentric, uncontrolled, non randomized clinical trial on Sodium Fluorescein for Surgery of High Grade Gliomas
Fondazione IRCCS Istituto Neurologico "Carlo Besta"

UOC Neurochirurgia 2 - Neurochirurgia Vascolare

Cooperative Multicenter Study for Children and Adolescents With Low Grade Glioma - PL
Instytut "Pomnik-Centrum Zdrowia Dziecka"

Klinika Onkologii IP-CZD

Cooperative Multicenter Study for Children and Adolescents With Low Grade Glioma - PT
Centro Hospitalar de S. João, EPE

Unidade de Hematologia e Oncologia Pediátrica

PARC: Phase I/II Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100) in Relapsed/Refractory Cancers of Children and Young Adults -GB
University of Birmingham

University of Birmingham HQ

CNS 2004 03: Cooperative Multicentre Study For Children And Adolescents With Low Grade Glioma (Phase III) (SIOP-LGG 2004) - UK
St James's University Hospital

Regional Paediatric Oncology Unit

CATNON (EORTC 26053-22054) - Phase III trial on concurrent and adjuvant Temozolomide chemotherapy in non-1p/19q deleted Anaplastic Glioma - DE
Neurologische Universitätsklinik Heidelberg

Abteilung für Neuroonkologie

EORTC 26052-22053 (RTOG 0525) : Phase III trial comparing conventional adjuvant Temozolomide with dose-intensive Temozolomide in patients with newly diagnosed Glioblastoma
Neurologische Universitätsklinik Heidelberg

Abteilung für Neuroonkologie

EORTC 26081-22086 (CODEL): Phase III intergroup study of Radiotherapy versus Temozolomide alone versus Radiotherapy with concomitant and adjuvant Temozolomide for patients with 1p/19q codeleted Anaplastic Glioma - DE
Neurologische Universitätsklinik Heidelberg

Abteilung für Neuroonkologie

TAVAREC (EORTC 26091) - Randomized trial assessing the significance of Bevacizumab in recurrent Grade II and Grade III Glioma (Phase II) - DE
Neurologische Universitätsklinik Heidelberg

Abteilung für Neuroonkologie

EORTC 26062-22061: A randomized phase III study of Temozolomide and short-course radiation versus short-course radiation alone in the treatment of newly diagnosed glioblastoma multiforme in elderly patients - DE
Neurologische Universitätsklinik Heidelberg

Abteilung für Neuroonkologie

EORTC 26101: Randomized phase II trial exploring the sequence of Bevacizumab and Lomustine in patients with first recurrence of a Glioblastoma
Neurologische Universitätsklinik Heidelberg

Abteilung für Neuroonkologie

A Phase II, multicenter, randomized, double-blind study of LY2157299 monohydrate monotherapy or LY2157299 monohydrate Plus Lomustine therapy compared to Lomustine monotherapy in patients with recurrent Glioblastoma - DE
Neurologische Universitätsklinik Heidelberg

Abteilung für Neuroonkologie

ABT-414 alone or ABT-414 plus Temozolomide versus Lomustine or Temozolomide for recurrent Glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group - DE
Neurologische Universitätsklinik Heidelberg

Abteilung für Neuroonkologie

NOA-20/Improvement of functional outcome for patients with newly diagnosed grade II or III glioma with co-deletion of 1p/19q - IMPROVE CODEL
Neurologische Universitätsklinik Heidelberg

Abteilung für Neuroonkologie

An open-label, Phase I/II multicenter clinical trial of VXM01 in combination with avelumab in patients with progressive glioblastoma following standard treatment with or without second surgery -DE-
Neurologische Universitätsklinik Heidelberg

Abteilung für Neuroonkologie

GERAS: Effect of Timing of Tumor-Treating Fields Plus Short-Course Radiation in Elderly Patients With Glioblastoma
Neurologische Universitätsklinik Heidelberg

Klinik für Radioonkologie und Strahlentherapie

Phase 3b Study for Management of Ocular Side Effects in Subjects With EGFR-amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414) -DE-
Universitätsklinikum Heidelberg

Impact of iMRI on the Extent of Resection in Patients With Newly Diagnosed Glioblastomas - A Prospective Multicenter Parallel Group Clinical Trial - DE
CCC Tübingen-Stuttgart

Comprehensive Cancer Center Tübingen-Stuttgart

Phase 3b Study for Management of Ocular Side Effects in Subjects With EGFR-amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414) -DE-
Universitätsklinikum Tübingen

GlioCave/NOA17: Adjuvant Stereotactic Fractionated Radiotherapy to the Resection Cavity in Recurrent Glioblastoma (Phase 2) - DE
Klinikum rechts der Isar der Technischen Universität München

Klinik und Poliklinik für RadioOnkologie und Strahlentherapie

Evaluation of the Feasibility of PD L 506 for Stereotactic Interstitial Photodynamic Therapy (iPDT) in Adult Patients With Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma
LMU Klinikum der Universität München - Campus Großhadern

Neurochirurgische Klinik und Poliklinik

Phase 3b Study for Management of Ocular Side Effects in Subjects With EGFR-amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414) -DE-
Universität Regensburg

The C-GBM Study: Prospective controlled phase II trial of Cabazitaxel in patients with Temozolomide refractory Glioblastoma Multiforme - DE
Charité - Universitätsmedizin Berlin (CVK)

Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie

Phase 3b Study for Management of Ocular Side Effects in Subjects With EGFR-amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414) -DE-
Hubertus Wald Tumorzentrum/ Universitäres Cancer Center (UCCH)

Comprehensive Cancer Center (CCC) Hamburg

A prospective, multicenter phase III trial of NovoTTF-100A together with Temozolomide compared to Temozolomide alone in patients with newly diagnosed Glioblastoma Multiforme (GBM)
UKE - Universitätsklinikum Hamburg-Eppendorf

Klinik und Poliklinik für Neurochirurgie

HIT-HGG-CilMetro: Cilengitide and Metronomic Temozolomide for relapsed or refractory high grade Gliomas or Diffuse Intrinsic Pontine Gliomas in children and adolescents - Prospective non- randomised phase II study
Universitätsmedizin Göttingen

Klinik für Kinder- und Jugendmedizin

Autologous Dendritic Cells and Metronomic Cyclophosphamide for Relapsed High-Grade Gliomas in Children and Adolescents
Universitätsmedizin Göttingen

Klinik für Kinder- und Jugendmedizin

GLORIA: Single-arm, Dose-Escalation, Phase 1/2 Study of Olaptesed Pegol (NOX-A12) in Combination with Irradiation in Inoperable or Partially Resected First-line Glioblastoma Patients with Unmethylated MGMT Promoter
Universitätsklinikum Bonn (AöR)

Klinik und Poliklinik für Neurologie

Phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy in newly diagnosed glioblastoma -DE-
Universitätsklinikum Düsseldorf

Klinik für Neurochirurgie

GLORIA: Single-arm, Dose-Escalation, Phase 1/2 Study of Olaptesed Pegol (NOX-A12) in Combination with Irradiation in Inoperable or Partially Resected First-line Glioblastoma Patients with Unmethylated MGMT Promoter
Universitätsklinikum Essen

Klinik für Neurologie

Phase 3b Study for Management of Ocular Side Effects in Subjects With EGFR-amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414) -DE-
Universitätsklinikum Leipzig AöR

UCCL - Universitäres Krebszentrum Leipzig

MIRAGE: A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma - AT
Institution: Information not provided - AT

IDH mutated 1p/19q intact lower grade glioma following resection: Wait Or Treat? IWOT - A phase III study - AT
Institution: Information not provided - AT

Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma - AT
Allgemeines Krankenhaus der Stadt Wien

Klinische Abteilung für Onkologie

STEAM: Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma: A Phase Ib Study - AT
Allgemeines Krankenhaus der Stadt Wien

Klinische Abteilung für Onkologie

Pharmacokinetics of temozolomide in cerebrospinal fluid in children with malignant brain tumors (phase 1)
Allgemeines Krankenhaus der Stadt Wien

Klinische Abteilung für Neonatologie, Pädiatrische Intensivmedizin und Neuropädiatrie

EORTC 26081-22086/CODEL: Phase III intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with concomitant and adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma - BE
Ziekenhuis Netwerk Antwerpen (ZNA) - Campus Middelheim

Oncologie

ADDIT-GLIO: Adjuvant Dendritic-Cell Immunotherapy Plus Temozolomide Following Surgery and Chemoradiation in Patients With Newly Diagnosed Glioblastoma
University Hospital of Antwerp - UZA

Antwerp University Hospital

TAVAREC: Randomized trial assessing the significance of Bevacizumab in recurrent grade II and Grade III gliomas. The TAVAREC trial (Phase II) - BE
Institution: Information not provided - BE

Phase IIb Trial Evaluations Of The Effectiveness Of Treatment Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 (Pembrolizumab) - BE
Cliniques universitaires Saint-Luc - UCLouvain

Cliniques Universitaires Saint-Luc

A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma
Universitair Ziekenhuis Brussel

NMRC Site UZBrussel

The CATNON Intergroup trial: Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma - BE
Universitair Ziekenhuis Brussel

Neurology

Phase II Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma
Universitair Ziekenhuis Brussel

Universitair Ziekenhuis Brussel (UZ Brussel)

CheckMate 548: Estudio fase 3, aleatorizado, simple ciego, de temozolomida más radioterapia combinados con nivolumab o placebo en sujetos adultos recién diagnosticados de glioblastoma con MGMT (06-metilguanina ADN metiltransferasa tumoral) metilado
Hospital Germans Trias I Pujol

CheckMate 548: Estudio fase 3, aleatorizado, simple ciego, de temozolomida más radioterapia combinados con nivolumab o placebo en sujetos adultos recién diagnosticados de glioblastoma con MGMT (06-metilguanina ADN metiltransferasa tumoral) metilado
Hospital Clínic de Barcelona

Estudio clínico de fase 2 de pomalidomida (CC-4047) en monoterapia para niños y adultos jóvenes con tumores cerebrales primarios recurrentes o progresivos
Hospital Universitari Vall d'Hebron

CheckMate 548: Estudio fase 3, aleatorizado, simple ciego, de temozolomida más radioterapia combinados con nivolumab o placebo en sujetos adultos recién diagnosticados de glioblastoma con MGMT (06-metilguanina ADN metiltransferasa tumoral) metilado
Hospital Universitari Vall d'Hebron

CheckMate 548: Estudio fase 3, aleatorizado, simple ciego, de temozolomida más radioterapia combinados con nivolumab o placebo en sujetos adultos recién diagnosticados de glioblastoma con MGMT (06-metilguanina ADN metiltransferasa tumoral) metilado
Hospital General Universitario de Valencia

Estudio clínico de fase 2 de pomalidomida (CC-4047) en monoterapia para niños y adultos jóvenes con tumores cerebrales primarios recurrentes o progresivos
Hospital Universitario y Politécnico La Fe

Ensayo de fase IIb de evaluación de la eficacia del tratamiento del glioblastoma / gliosarcoma mediante la supresión de la vía PI3K/Akt en comparación con MK-3475 (pembrolizumab)
Institution: Information not provided - ES

Estudio clínico de fase 2 de pomalidomida (CC-4047) en monoterapia para niños y adultos jóvenes con tumores cerebrales primarios recurrentes o progresivos
Hospital Infantil Universitario Niño Jesús

CheckMate 548: Estudio fase 3, aleatorizado, simple ciego, de temozolomida más radioterapia combinados con nivolumab o placebo en sujetos adultos recién diagnosticados de glioblastoma con MGMT (06-metilguanina ADN metiltransferasa tumoral) metilado
Hospital Universitario 12 de Octubre

GEINOGLAS: Ensayo clínico fase Ib/II sobre la combinación de glasdegib (inhibidor de la vía SHH) y temozolamida en pacientes con diagnóstico de novo de glioblastoma
Hospital Universitario Ramón y Cajal

Servicio de Oncología Médica

A Phase I Study of Cytosine Deaminase-Expressing Neural Stem Cells in Combination With Oral 5-Fluorocytosine and Leucovorin for the Treatment of Recurrent High-Grade Gliomas - US
City of Hope

City of Hope National Medical Center

A Phase 2, Investigator Initiated Study to Determine the Safety and Efficacy of TH-302 in Combination With Bevacizumab for Glioblastoma Following Bevacizumab Failure - US
University of Texas Health Science Center

Randomized, Prospective, Multicenter Blinding Singles With Arm A and Arm B Innovative Strategy Strategy Conventional (Phase III) - FR
CHU de Lyon HCL - GH Est-Hôpital Neurologique P. Wertheimer

Service de neurochirurgie tumorale - chirurgie des malformations vasculaires du systéme nerveux

GLYRad : Phase I/II Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma
CLCC Jean Perrin

Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma- A Randomized Multicenter Trial (Phase III) - FR
CHU Paris Seine-Saint-Denis - Hôpital Avicenne

Service de Neurologie

A Prospective, Multi-center Phase III Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed Glioblastoma Multiforme
APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière

Service de Neurologie 2 : Unité d'Onco-Neurologie

ONCOVIRAC : Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients (Phase I-II)
APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière

Service de Neurologie 2 : Unité d'Onco-Neurologie

Phase III intergroup study of radiotherapy versus temozolomide alone versus radiotherapy with concomitant and adjuvant temozolomide for patients with 1p/19q codeleted anaplastic glioma - FR
CLCC Institut Gustave Roussy

Département d'Oncologie Radiothérapie